Minze Health NV closed on $4.1 million of seed funding to develop its digital solution for the treatment of urinary tract problems. Three major Belgian funds participated in this seed round, led by White Fund SA, a private equity fund focusing on med-tech. Capricorn Partners NV joined White Fund via its Digital Growth fund, alongside Flemish investment company PMV NV.
Vevo Therapeutics Inc. raised $12 million in an over-subscribed seed round to build out an in vivosingle-cell screening platform, which will enable it to interrogate simultaneously the effects of small molecule drug leads on multiple cancer cell lines.
Apogee Therapeutics Inc. emerged from stealth with $169 million in financing and a pipeline of four preclinical antibody development programs that take aim at major immunological and inflammatory disorders.
Wangli Technology, a subsidiary of Adai Technology (Beijing) Co. Ltd., has raised ¥100 million (US$14 million) to continue developing digital therapeutics aimed at mental health indications.
Biopharma financings are tracking only 3% below 2019’s full-year total, but the volume of activity is at its lowest point since 2017. With a total of $56.1 billion raised, 2022 is currently the sixth best financing year on record, but it is significantly behind some of the years that rank higher.